On April 20, 2020, Idorsia announced positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia.
Find information on this page to support you with covering the news.
Jean-Paul Clozel - Chief Executive Officer
Guy Braunstein - Head of Global Clinical Development
Simon Jose - Chief Commercial Officer
Martine Clozel - Chief Scientific Officer
Share this page:
First quarter 2020 financial results
On April 23, 2020, Idorsia announced its financial results for the first quarter of 2020. For more information please visit the Results Day Center.